Search for content, post, videos

Affibody presents topline 12-week data

Nikolai Brun
Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented. The data from the open label Part A, presented at the American Academy of Dermatology (AAD) Annu
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.